Étiquette : anxiété

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, P.S. Hendricks et al., 2015

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population Peter S Hendricks, Christopher B Thorne, C Brendan Clark, David W Coombs, and Matthew W Johnson Journal of Psychopharmacology · January 2015 DOI: 10.1177/0269881114565653 ·   Abstract : Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA [...]

Lire la suite

Cannabidiol in Anxiety and Sleep : A Large Case Series, S. Shannon et al. , 2019

Cannabidiol in Anxiety and Sleep : A Large Case Series SHANNON S., LEWIS N., LEE H., HUGHES S. The Permanente Journal, 2019, 23   Abstract CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a "high." A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of [...]

Lire la suite

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus : Cannabidiol Blunts Δ9Tetrahydrocannabinol-Induced Cognitive Impairment, Ester Aso et al., 2019

Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus : Cannabidiol Blunts Δ9Tetrahydrocannabinol-Induced Cognitive Impairment Ester Aso, Víctor Fernández-Dueñas, Marc López-Cano, Jaume Taura, Masahiko Watanabe, Isidre Ferrer, Rafael Luján, Francisco Ciruela, Ester Aso Molecular Neurobiology, First Online: 04 January 2019, pp 1-10. C : Springer Nature Switzerland AG Abstract : At present, clinical interest in the plant-derived cannabinoid compound cannabidiol (CBD) is rising exponentially, since it displays multiple therapeutic properties. In addition, CBD can counteract the undesirable effects of the psychoactive cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) that hinder clinical development of cannabis-based therapies. Despite this attention, the mechanisms of CBD action and its interaction with Δ9-THC are still not completely elucidated. Here, by combining in vivo [...]

Lire la suite

Clinical Manifestations of Cannabis Use Disorder, Alan J. Budney et al., 2019

Clinical Manifestations of Cannabis Use Disorder Alan J. Budney, Jacob T. Borodovsky, and Ashley A. Knapp C Springer Nature Switzerland AG 2019   Introduction : Cannabis use disorder (CUD) or its colloquial synonym, cannabis addiction, remains controversial in that many in the general public believe that cannabis use does not pose substantial risk for harm and is not addictive in the same sense that tobacco, alcohol, cocaine, or heroin is addictive. Although assessment of people’s beliefs about addiction and harm is complicated by the lack of a consensus definition or a common understanding of addiction, the difference in perception of risk between cannabis and other [...]

Lire la suite

Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities, D. Barchel et al., Frontiers in Pharmacology, Tel Aviv, 2019

Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. Frontiers in Pharmacology, 2019, 9, 1521. doi : 10.3389/fphar.2018.01521,   PMID : 30687090   Objective: Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. In this study we aimed to report the experience of parents who administer, under supervision, oral [...]

Lire la suite

What Is the CBD Dosing Required for Effective Pain Relief ? Medscape, 14/12/2018

What Is the CBD Dosing Required for Effective Pain Relief ? Damian McNamara, CME, Laurie Barclay, MD Posted: 12/14/2018 Clinical Context The effects of cannabis in humans include euphoria, increased sensitivity to external experience, relaxation, and potential for addiction. Cannabidiol is a compound in the cannabis plant that lacks euphoric and addictive qualities and that may be useful to treat conditions including chronic pain, nausea, epilepsy, psychosis, and anxiety. The optimal therapeutic dose of CBD has not yet been determined, and it has been used in a wide dose range from 2.85 to 50 mg/kg/day. The therapeutic effects of CBD appear to emanate from its interaction [...]

Lire la suite

Interactions du CBD avec des médicaments sous ordonnance, blog-cannabis.com, repris sur Principesactifs.org, 2019

Interactions du CBD avec des médicaments sous ordonnance Source : blog-cannabis.com, repris sur Principesactifs.org, 2019 Le CBD est considéré comme bénin, mais il existe beaucoup d’interactions médicamenteuses à éviter avec les médicaments sous ordonnance… "Le CBD fait fureur, ce cannabinoïde non toxique a une tonne d’avantages médicaux. Les gens de tous âges utilisent le CBD pour traiter des problèmes médicaux graves comme l’épilepsie, la maladie de Parkinson, ainsi que des problèmes de santé mentale comme l’anxiété, la dépression et la toxicomanie. Mais il est important d’apprendre comment il peut interagir avec d’autres médicaments sous ordonnance." https://www.principesactifs.org/interactions-du-cdb-avec-des-medicaments-sous-ordonnance/

Lire la suite

Cannabidiol (CBD) : analyse de situation, Rapport de Recherche n° 97, “Addiction Suisse”, 2019

Cannabidiol (CBD) : analyse de situation Frank ZOBEL, Luca NOTARI, Eva SCHNEIDER, Ocyna RUDMANN Addiction Suisse, Lausanne, janvier 2019 Rapport de recherche N° 97 https://www.addictionsuisse.ch/fileadmin/user_upload/DocUpload/Rapport-CBD-final.pdf   Table des matières Liste des tableaux Liste des graphiques 1 Introduction 2 Méthode 3 Brève analyse de la littérature sur les effets du Cannabidiol (CBD) 3.1 Méthode 3.2 Usages du CBD et effets 3.3 Pourquoi prendre du CBD? Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine somatique Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine psychique Traitement/prévention de maladies chroniques et neurodégénératives, renforcement du système immunitaire . Traitement de troubles neurologiques diagnostiqués . Autres 3.4 Que sait-on de ces effets à ce jour? 3.5 Le CBD peut-il [...]

Lire la suite

Medical cannabis : An oxymoron ? Physicians’ perceptions of medical cannabis, Yuval ZOLOTOVA et al., 2018

Medical cannabis : An oxymoron ? Physicians’ perceptions of medical cannabis Yuval ZOLOTOVA, Simon VULFSONS, Dana ZARHIN, Sharon SZNITMAN International Journal of Drug Policy, 2018, 57, 4-10.   A B S T R A C T : Background : Medical cannabis policies are changing in many places around the world, and physicians play a major role in the implementation of these policies. The aim of this study was to gain a deeper understanding of physicians’ views on medical cannabis and its possible integration into their clinic, as well as to identify potential underlying factors that influence these perceptions. Methods : Qualitative narrative analysis of in-depth interviews [...]

Lire la suite

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies, Kerstin IFFLAND, Franjo GROTENHERMEN, 2017

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Kerstin IFFLAND, Franjo GROTENHERMEN Cannabis and Cannabinoid Research, 2017, 2, (1), 139–154. DOI: 10.1089/can.2016.0034 https://www.liebertpub.com/doi/10.1089/can.2016.0034?utm_source=sfmc&utm_medium=email&utm_campaign=CAN%20OA%20Feb%201%202019&d=2/1/2019&mcid=1909944349   Abstract Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was confirmed and extended by the reviewed research. The majority of studies were performed for treatment of epilepsy [...]

Lire la suite